Linked Life Data

7785989

Source:http://linkedlifedata.com/resource/pubmed/id/7785989

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1995-7-20
pubmed:abstractText
Cidofovir (HPMPC; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine) is a nucleotide analog with activity against human cytomegalovirus (CMV). A phase I/II dose escalation trial was conducted with asymptomatic human immunodeficiency virus (HIV)-infected patients with CMV viruria to determine its pharmacokinetics, maximally tolerated dose, and preliminary antiviral activity against CMV. Qualitative CMV blood and urine cultures were monitored weekly to assess anti-CMV activity. Twenty-one HIV-infected persons with CD4 counts from 0 to 389 cells per microliters (median, 39) were enrolled in six dose-ranging groups. The first five groups enrolled four patients each to receive cidofovir infusions either weekly or biweekly for 4 weeks or every 3 weeks for 12 weeks. The sixth group enrolled one patient who received infusions of 5 mg/kg of body weight every other week. Patients receiving 0.5 or 1.5 mg/kg twice weekly experienced no serious toxicity. The first two patients who received 5 mg/kg twice weekly developed glycosuria and 2+ proteinuria. Subsequent patients received concomitant probenecid to attempt to ameliorate renal toxicity. Seventeen patients experienced proteinuria on one or more occasions; 6 of them experienced at least 2+ proteinuria. Four patients did not complete the study as planned because of renal toxicity. Positive CMV urine cultures reverted to negative in 2 of 8 patients receiving doses of < or = 1.5 mg/kg twice weekly and 11 of 13 patients receiving higher doses. Cidofovir has in vivo anti-CMV activity demonstrated by prolonged clearing of CMV viruria, although this observation is tempered by the fact that clearance of viremia could not be demonstrated. The dose-limiting toxicity is renal; however, concurrent administration of probenecid may be protective. The maximally tolerated weekly intravenous dose with probenecid is approximately 5 mg/kg. Efficacy trials with CMV disease will define the therapeutic utility and optimal dosing interval for cidofovir.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7785989-1656826, http://linkedlifedata.com/resource/pubmed/commentcorrection/7785989-1663727, http://linkedlifedata.com/resource/pubmed/commentcorrection/7785989-1663729, http://linkedlifedata.com/resource/pubmed/commentcorrection/7785989-1666493, http://linkedlifedata.com/resource/pubmed/commentcorrection/7785989-1733387, http://linkedlifedata.com/resource/pubmed/commentcorrection/7785989-1849157, http://linkedlifedata.com/resource/pubmed/commentcorrection/7785989-1970102, http://linkedlifedata.com/resource/pubmed/commentcorrection/7785989-1980687, http://linkedlifedata.com/resource/pubmed/commentcorrection/7785989-2171213, http://linkedlifedata.com/resource/pubmed/commentcorrection/7785989-2403474, http://linkedlifedata.com/resource/pubmed/commentcorrection/7785989-2544723, http://linkedlifedata.com/resource/pubmed/commentcorrection/7785989-3451698, http://linkedlifedata.com/resource/pubmed/commentcorrection/7785989-6328055, http://linkedlifedata.com/resource/pubmed/commentcorrection/7785989-7840578, http://linkedlifedata.com/resource/pubmed/commentcorrection/7785989-7902536, http://linkedlifedata.com/resource/pubmed/commentcorrection/7785989-8093214
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
39
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
882-6
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria.
pubmed:affiliation
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
pubmed:publicationType
Journal Article